Aniogo Eric Chekwube, George Blassan Plackal Adimuriyil, Abrahamse Heidi
a Laser Research Centre, Faculty of Health Sciences , University of Johannesburg , Doornfontein , South Africa.
Expert Rev Anticancer Ther. 2017 Aug;17(8):693-702. doi: 10.1080/14737140.2017.1347505. Epub 2017 Jul 3.
Globally, breast cancer is the most common life-threatening malignant disease among women. Adjuvant chemotherapeutic treatment of anthracycline-based chemotherapy (e.g., doxorubicin) has been shown to be more advantageous over non-anthracycline-based therapies, yet possess the tenacity of developing resistance and potential side effects which have limited its use in the clinical setting. These reasons necessitate combining doxorubicin with emerging photodynamic treatment regimens. Areas covered: In this review, the authors have concisely explained doxorubicin chemotherapy and the photobiological processes of phthalocyanine triggered photodynamic therapy (PDT). A literature search was conducted and reports demonstrating the use of doxorubicin and photodynamic therapy as a treatment modality for breast cancer were identified. More emphasis was made on studies demonstrating the efficacy and improved anticancer effect of combining chemotherapy with photodynamic therapy. However, it was concluded that for this combination therapy, still in it's infancy, it could be relevant when integrated into standard treatment. Expert Commentary: To these effects, comprehensive models based on experimental evaluations are needed for rational design of anthracycline-based chemotherapy and PDT to be integrated into the clinical setting.
在全球范围内，乳腺癌是女性中最常见的危及生命的恶性疾病。基于蒽环类药物的化疗（如多柔比星）辅助化疗已被证明比非蒽环类药物疗法更具优势，但仍存在产生耐药性的问题以及潜在的副作用，这限制了其在临床中的应用。这些原因使得有必要将多柔比星与新兴的光动力治疗方案相结合。涵盖领域：在本综述中，作者简要解释了多柔比星化疗以及酞菁引发的光动力疗法（PDT）的光生物学过程。进行了文献检索，并确定了证明使用多柔比星和光动力疗法作为乳腺癌治疗方式的报告。更多的重点放在了证明化疗与光动力疗法联合使用的疗效和增强抗癌效果的研究上。然而，得出的结论是，对于这种仍处于起步阶段的联合疗法，当整合到标准治疗中时可能会有意义。专家评论：针对这些影响，需要基于实验评估的综合模型，以便合理设计基于蒽环类药物的化疗和光动力疗法并将其整合到临床环境中。
